

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Simon Ward et al.

Application No.: 10/085,239

Confirmation No.: 1714

Filed: February 27, 2002

Art Unit: 1629

For: Treatment Of Hyperproliferative Diseases

Examiner: L. A. Royds

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

Furthermore, in accordance with 37 CFR 1.704(d), Applicant(s) note(s) that to our knowledge each item of information contained in the information disclosure statement was first

cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the information disclosure statement.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 50-0311, under Order No. 42033-505N01US.

Dated: July 5, 2011

Respectfully submitted,

/Sean M. Coughlin/  
Sean M. Coughlin, Esq.  
Registration No.: 48,593  
MINTZ LEVIN COHN FERRIS GLOVSKY  
AND POPEO, P.C.  
3580 Carmel Mountain Road, Suite 300  
San Diego, California 92130-6768  
(858) 314-1500  
(858) 314-1501 (Fax)  
Attorneys for Applicant